share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股sec公告 ·  06/26 16:54
Moomoo AI 已提取核心訊息
On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.
On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.
2024年6月24日，Avenue Therapeutics， Inc。舉行了股東的年度股東大會，做出了幾項關鍵決定。股東們批准了對2015年激勵計劃的修正案，將授權發行的股份數量增加了500萬股，將計劃期限延長到2034年，並將非員工董事獎項的年度股票限制提高到50萬股。董事會此前已批准了該修正案，該修正案在股東批准後生效。此外，六名董事被選舉爲2025年年度股東大會的服務期，KPMG LLP獲得了2024財年獨立註冊公共會計師事務所的認可。會議通過虛擬方式進行，出席的法定人數代表了佔外部投票權的大多數。關於董事選舉、會計師事務所認可和2015計劃修正案的投票結果詳細披露，大多數投票投贊同票。
2024年6月24日，Avenue Therapeutics， Inc。舉行了股東的年度股東大會，做出了幾項關鍵決定。股東們批准了對2015年激勵計劃的修正案，將授權發行的股份數量增加了500萬股，將計劃期限延長到2034年，並將非員工董事獎項的年度股票限制提高到50萬股。董事會此前已批准了該修正案，該修正案在股東批准後生效。此外，六名董事被選舉爲2025年年度股東大會的服務期，KPMG LLP獲得了2024財年獨立註冊公共會計師事務所的認可。會議通過虛擬方式進行，出席的法定人數代表了佔外部投票權的大多數。關於董事選舉、會計師事務所認可和2015計劃修正案的投票結果詳細披露，大多數投票投贊同票。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息